CD22 and systemic inflammatory response syndrome: Currently, various groups are working on addressing different targets such as CD22 for patients with CD19 negative relapses, optimizing the dose of CAR-T cells, and standardizing the management of neurological toxicity and systemic inflammatory response syndrome (SIRS) [254].